On October 22, 2026 Daiichi Sankyo (TSE: 4568) reported it will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society for Medical Oncology (#ESMO26) Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast and lung cancer, including the DESTINY-Breast05 (539RO), DESTINY-Breast06 (4279P), DESTINY-Breast09 (LBA49), DESTINY-Breast11 (543RO) and DESTINY-Lung04 (LBA74) phase 3 trials of Enhertu (trastuzumab deruxtecan) and the TROPION-Breast02 (LBA96) phase 3 trial of Datroway (datopotamab deruxtecan).

Additional data at ESMO (Free ESMO Whitepaper) also will spotlight the company’s commitment to advancing research for patients with advanced ovarian cancer across lines of therapy. An updated analysis, including progression-free survival and duration of response, will be presented from the REJOICE-Ovarian01 (1331P) phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. A mini oral presentation will highlight preliminary findings from the REJOICE-Ovarian02 (1247RO) phase 1b/2 trial evaluating raludotatug deruxtecan in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

"The promising data for raludotatug deruxtecan in ovarian cancer and the robust scientific innovation demonstrated across our pipeline reflects our progress in advancing research for patients across multiple types of cancer," said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. "Daiichi Sankyo continues to draw from its scientific and technological expertise to turn science into new medicines that can change the standard of care."

Data Demonstrate Benefit of DXd ADCs in Patients with Brain Metastases
Research updates highlighting the impact of DXd ADCs in patients with brain metastases include late-breaking rapid oral and proffered paper presentations from the DESTINY-Breast09 (LBA49) phase 3 trial evaluating Enhertu in combination with pertuzumab as a first-line treatment for patients with HER2 positive metastatic breast cancer and the TROPION-Breast02 (LBA96) phase 3 trial evaluating Datroway as a first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option. Final overall survival results of the TUXEDO-3 (690O) phase 2 trial of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases from metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) or leptomeningeal disease from any solid tumor will be presented as a proffered paper.

New Data and Trials-in-Progress Presentations Across DXd ADC Portfolio
Additional data highlighting new research across the DXd ADC portfolio include oral and poster presentations, including final results of the TALENT (LBA23) phase 2 trial of Enhertu alone or in combination with anastrozole, or in sequence with chemotherapy, as neoadjuvant treatment for patients with HR positive, HER2 low early stage breast cancer. New data in NSCLC include the NeoCOAST-2 (4244RO) phase 2 trial reporting event-free survival results, as well as findings on the association of ctDNA clearance with clinical outcomes in patients with resectable, early stage NSCLC treated with a combination of Datroway plus durvalumab and chemotherapy, and a retrospective analysis evaluating mechanisms of insensitivity to the Datroway payload in subgroups of patients with advanced NSCLC in the TROPION-Lung01 (4451P) phase 3 trial. Updated findings from the EPOC2003 (2888P) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer: results from ESPERANZA (1014P), an external comparator study evaluating Enhertu versus real-world standard of care as a second line or later treatment for patients with HER2 IHC 3+ solid tumors; and, the primary analysis evaluating patritumab deruxtecan monotherapy in patients with melanoma in the HERTHENA-PanTumor01 (2073RO) phase 2 trial also will be presented.

Trials-in-progress poster presentations include the DESTINY-Breast Guide (1795TiP) prospective and interventional trial evaluating first-line treatment with Enhertu plus pertuzumab followed by palbociclib, endocrine therapy and dual HER2 blockade (trastuzumab plus pertuzumab), as well as retreatment with Enhertu following progression on maintenance therapy (palbociclib, endocrine therapy and trastuzumab plus pertuzumab) in previously untreated patients with HER2 positive advanced or metastatic breast cancer and the TROY (1335TiP) phase 2 trial evaluating Enhertu in patients with recurrent ovarian cancer with disease progression on prior PARP inhibitor therapy.

An overview of late-breaking, clinical data and trials-in-progress presentations from the ADC portfolio of Daiichi Sankyo includes:

Presentation Title
Author

Abstract

Presentation (CEST)

LBAs

Final results of TALENT: a neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

S. Hurvitz

LBA23

Proffered Paper Presentation

Friday, October 23

1:30 pm – 3:00 pm

First-line datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: exploratory analysis of patients with brain metastases in TROPION-Breast02

R. Dent

LBA96

Proffered Paper Presentation

Saturday, October 24

8:30 am – 10:00 am

First-line trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant NSCLC: patient-reported outcomes from DESTINY-Lung04

S. Novello

LBA74

Rapid Oral Presentation

Saturday, October 24

8:30 am – 10:00 am

DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab for patients with HER2+ advanced/metastatic breast cancer and baseline brain metastases

C. Saura

LBA49

Rapid Oral Presentation

Monday, October 26

10:15 am – 11:45 am

Breast

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab vs. dose-dense doxorubicin + cyclophosphamide followed by THP in HER2+ early breast cancer

J.F. Boileau

543RO

Rapid Oral Presentation

Friday, October 23

4:15 pm – 5:45 pm

Patient-reported outcomes from DESTINY-Breast05: health-related quality of life with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2 positive early breast cancer

C. Barrios

539RO

Rapid Oral Presentation

Friday, October 23

4:15 pm – 5:45 pm

Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody-drug conjugate resistance in metastatic breast cancer

P. Tarantino

4449RO

Rapid Oral Presentation

Monday, October 26

10:15 am – 11:45 am

Trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy in HR+, HER2 low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis

G. Curigliano

4279P

Poster Presentation

Friday, October 23

3:15 pm – 4:00 pm

Trastuzumab deruxtecan (T-DXd) + pembrolizumab in previously treated human epidermal growth factor receptor 2-expressing advanced or metastatic breast cancer: primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106

H. Rugo

1771P

Poster Presentation

Saturday, October 24

12:00 pm – 12:45 pm

DESTINY-Breast Respond HER2 low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2 low metastatic breast cancer: update on baseline characteristics and anti-emetic treatment

J.Y. Pierga

12P

Poster Presentation

Saturday, October 24

12:00 pm – 12:45 pm

Improving accuracy in HER2 ultralow identification: multi-site validation of an AI-decision support tool

B. Van der Vegt

1784P

Poster Presentation

Saturday, October 24

12:00 pm – 12:45 pm

Comparative evaluation of 7 artificial intelligence tools for HER2-low and ultralow scoring in breast cancer

J.S. Frenel

287P

Poster Presentation

Sunday, October 25

12:00 pm – 12:45 pm

A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy, and dual HER2 blockade in first-line human epidermal growth factor receptor positive, hormone receptor-positive advanced or metastatic breast cancer and retreatment with T-DXd (DESTINY-Breast Guide)

S. Sammons

1795TiP

Poster Presentation

Saturday, October 24

12:00 pm – 12:45 pm

Lung

NeoCOAST-2: association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial

T. Cascone

4244RO

Rapid Oral Presentation

Sunday, October 25

8:30 am – 10:00 am

Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer in TROPION Lung01

N. Girard

4451P

Poster Presentation

Friday, October 23

3:15 pm – 4:00 pm

Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: IDeate-Lung01 updated results

M. Ahn

3842P

Poster Presentation

Monday, October 26

12:00 pm – 12:45 pm

Ovarian

Raludotatug deruxtecan (R-DXd) + bevacizumab in participants with platinum-resistant recurrent ovarian cancer: results for cohort B-1 of the phase 1b/2 REJOICE-Ovarian02 study

A. Oaknin

1247RO

Rapid Oral Presentation

Saturday, October 24

08:30 am – 10:00 am

Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: an updated analysis of efficacy and tolerability from the phase 2 part of REJOICE-Ovarian01

K. Hasegawa

1331P

Poster Presentation

Monday, October 26

12:00 pm – 12:45 pm

A randomized phase 2, open-label, multicenter, study of trastuzumab deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14)

J.Y. Lee

1335TiP

Poster Presentation

Monday, October 26

12:00 pm – 12:45 pm

Gastric

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma from DESTINY-Gastric04

M. Gumus

2925P

Poster Presentation

Sunday, October 25

12:00 pm – 12:45 pm

Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2 positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003)

D. Takahari

2888P

Poster Presentation

Sunday, October 25

12:00 pm – 12:45 pm

PanTumor

Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases and leptomeningeal disease

M. Preusser

690O

Proffered Paper Presentation

Sunday, October 25

10:15 am – 11:45 am

Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: primary analysis from HERTHENA-PanTumor01

M. McKean

2073RO

Rapid Oral Presentation

Sunday, October 25

10:15 am – 11:45 am

ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors

F. Meric-Bernstam

1014P

Poster Presentation

Friday, October 23

3:15 pm – 4:00 pm

(Press release, Daiichi Sankyo, OCT 22, 2026, View Source [SID1234673678])

On October 22, 2026 AbCellera (Nasdaq: ABCL) reported that the Company will present at the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Healthcare Conference, November 11, 2026
Jefferies Global Healthcare Conference in London, November 16, 2026

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

(Press release, AbCellera, OCT 22, 2026, View Source [SID1234673677])

On October 22, 2026 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, reported that company management will participate in two upcoming investor conferences in November.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA

Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET
Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK

Members of management will be available for 1×1 meetings on Thursday, November 19, 2026
The live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.

(Press release, Adicet Bio, OCT 22, 2026, View Source [SID1234673676])

On October 22, 2026 Boehringer Ingelheim and Microsoft reported a strategic collaboration that aims to bring safe and effective therapies to patients sooner fueled by AI. The collaboration will focus on jointly investigating the potential of Digital Patient Twins in clinical development. Digital Patient Twins are computational representations of individual patients that use clinical and other relevant data to predict how a disease might progress and how outcomes could evolve under different scenarios.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The joint research will explore disease-progression modelling, predictive outcome modelling and advanced trial simulation, including whether these approaches could support synthetic or hybrid control arms, which are alternatives to a conventional clinical control group, using existing data, and in the case of hybrid control arms, a combination of both.

In the end, the research may help reduce the number of patients required in control groups, accelerate the generation of clinical evidence, and improve clinical trial design. This way patients could potentially get faster access to innovative medicines, allow more trial participants to benefit from new treatments and increase the efficiency of drug development. Using clinical and other relevant data, these computational models may improve clinical research and evidence generation, with the aim of bringing new therapies to patients faster.

"The collaboration with Boehringer Ingelheim brings together pharmaceutical and scientific expertise with Microsoft’s capabilities in AI and engineering. Germany is home to world-class pharmaceutical research and development. Together, we want to explore how technology could open new opportunities for clinical research," says Agnes Heftberger, Corporate Vice President and CEO of Microsoft Germany and Austria.

Boehringer Ingelheim and Microsoft intend to assess scientific and technical feasibility through modeling, prototyping and evidence generation across multiple disease and therapeutic areas, starting with lung health.

"Boehringer Ingelheim is developing the richest pipeline in its history, and it is our goal to make clinical research more responsive to patients’ unmet needs. Exploring AI-enabled approaches, including the future potential of Digital Patient Twins, could support more patient-centric, informed and efficient clinical research," said Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim. "Crucially, scientific quality, patient safety and regulatory requirements must always be upheld. This partnership supports us in pursuing that ambition responsibly and in compliance with applicable requirements."

AI transformation across the entire workforce
Boehringer Ingelheim aims to become a Frontier AI company in Human Pharma and Animal Health by embedding AI responsibly across its value chain. Building on one of the largest Microsoft Copilot deployments in the pharmaceutical industry, the company is combining broad employee access with role-based use cases, skills development, governance and secure technology foundations.

"Successful AI adoption depends on more than technology alone," said Harsha Deshmukh, Member of the Board of Managing Directors at Boehringer Ingelheim, responsible for IT and Global Business Services. "What matters is enabling our employees to use AI responsibly and unlock its potential through scalable solutions across the complete value chain and all business units."

The partnership also encompasses security and datacenter modernization, supporting a secure, resilient and future-ready technology foundation for AI-enabled innovation. The partners are also exploring potential co-development projects in other areas, including Animal Health, business processes and technology infrastructure.

(Press release, Boehringer Ingelheim, OCT 22, 2026, View Source [SID1234673675])

On October 22, 2026 Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") reported that members of its management team will participate in presentations at the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts: Monday, Nov. 9 at 1 p.m. ET
Jefferies Global Healthcare Conference, London, UK: Monday, Nov. 16 at 10:30 a.m. ET

To access live webcasts of Generate’s presentations, please visit the "Events & Presentations" page within the Investors section of Generate’s website at View Source A replay of the webcasts will be available on Generate’s website for 90 days following the event.

(Press release, Generate Biomedicines, OCT 22, 2026, View Source;docid=6ba9a3d7c8647b1a8432de7fcd321c6a870ffe59&content=prnews&format=html [SID1234673674])